MacroGenics Shares Fall 10% After Lorigerlimab Trial Data
Shares fell to $2.02 after trial data for the investigational cancer treatment showed high rates of severe side effects, including one patient death, and a high dropout rate.
By Adriano MarcheseMacrogenics shares fell Monday after trial data for its investigational cancer treatment lorigerlimab showed high rates of severe side effects, including one patient death, as well as a high dropout rate.Shares fell 10% to $2.02.The biopharmaceutical company said the bispecific a…